SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Danaher Corporation DHR-PB NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Danaher Corporation (DHR-PB) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $1,261.26. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $24.6B, -7.1%/yr average growth. Net income is $3.6B, growing at -19.8%/yr. Net profit margin is 14.7% (healthy). Gross margin is 60.9% (+0.7 pp trend).

Balance sheet: total debt is $18.4B against $52.5B equity (Debt-to-Equity (D/E) ratio 0.35, conservative). Current ratio is 1.87 (strong liquidity). Debt-to-assets is 22.1%. Total assets: $83.5B.

Analyst outlook: 5 / 8 analysts rate DHR-PB as buy (63%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 15/100 (Fail), Past 100/100 (Pass), Health 100/100 (Pass), Moat 92/100 (Pass), Future 55/100 (Partial), Income 55/100 (Partial).

DHR-PB SharesGrow Score Overview

62/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 92/100

Gross margin is + market cap

FUTURE 55/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DHR-PB

DHR-PB trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

DHR-PB: -7.1%/yr revenue is, -19.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

DHR-PB: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet DHR-PB: Debt-to-Equity (D/E) ratio 0.35 (conservative), Current ratio is 1.87 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

DHR-PB: Gross margin is 60.9% (+0.7 pp trend), $917B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 92/100. ≥ 70 = Pass.

View details →

Analyst outlook: 5 / 8 analysts rate DHR-PB as buy (63%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

DHR-PB: Net profit margin is 14.7%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1199.99-1521.85

Volume152.33K

Avg Volume (30D)12.97K

Market Cap$916.76B

Beta (1Y)0.80

Dividend Yield$50.0000

Share Statistics

EPS (TTM)5.07

Shares Outstanding$707.3M

IPO Date2020-05-11

Employees79,000

CEORainer M. Blair

Financial Highlights & Ratios

Revenue (TTM)$24.57B

Gross Profit$14.97B

EBITDA$6.95B

Net Income$3.61B

Operating Income$5.14B

Total Cash$4.62B

Total Debt$18.42B

Net Debt$13.8B

Total Assets$83.46B

Price / Earnings (P/E)248.8

Price / Sales (P/S)37.32

Analyst Forecast

Rating ConsensusBuy

Analysts Covering8

Buy 63% Hold 38% Sell 0%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS2358514097

Price Chart

DHR-PB

Danaher Corporation ↗ · NYSE

Healthcare • Medical - Diagnostics & Research

1,199.99 52WK RANGE 1,521.85

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message